Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors

Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors

Background/Objective To assess safety/efficacy of tofacitinib and tumor necrosis factor inhibitors (TNFi) in patients from Latin America (LATAM) in ORAL Surveillance. Methods In ORAL Surveillance, 4362 patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gustavo Citera, Eduardo Mysler, Adriana María Kakehasi, Virginia Pascual‐Ramos, Walter Massón, Mary Jane Cadatal, Jose L. Rivas, Farzad Sheibanie, Claudia Helling, Darío Ponce de León
Formato: Artigo
Lenguaje:inglés
Publicado: 2024
Acceso en línea:https://doi.org/10.1097/rhu.0000000000002106
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doi.org/10.1097/rhu.0000000000002106

Ejemplares similares